International Consensus Urges Early Surgery for Hypothalamic Hamartomas

Navigating the Complexity of Hypothalamic Hamartomas

Hypothalamic hamartomas are rare, deep-seated brain lesions that frequently present with a complex triad of refractory epilepsy, cognitive decline, and endocrine dysfunction [1, 2]. Because these lesions are highly epileptogenic and often lead to developmental and epileptic encephalopathies (conditions where frequent epileptic activity directly contributes to severe cognitive and behavioral impairments), achieving seizure freedom is notoriously difficult [2]. While surgical techniques such as direct resection yield overall seizure-free rates of 79.2 percent at one year [3], and stereotactic radiofrequency ablation (a minimally invasive procedure using heat to destroy targeted tissue) provides effective lesion disconnection [4], clinical management remains highly variable [3, 5]. To resolve this uncertainty, a newly published international consensus from 17 epilepsy centers establishes a standardized clinical roadmap, recommending surgical evaluation at the initiation of the first antiseizure medication and proceeding to surgery after the failure of two medications [6]. The consensus further dictates that clinicians must utilize a 3-Tesla epilepsy protocol magnetic resonance imaging (MRI) scan for diagnosis and perform comprehensive neuropsychological and endocrinologic evaluations both at baseline and six to twelve months postoperatively to optimize patient outcomes [6].

Establishing the First International Consensus

Because hypothalamic hamartomas are exceptionally rare, worldwide treatment protocols remain highly varied and lack high-quality evidence to guide clinical decisions. To address this gap, the Medical Advisory Board of Hope for Hypothalamic Hamartomas designed a modified Delphi survey (a structured methodology that aggregates expert opinions through iterative rounds of questioning to reach a formal agreement). The researchers conducted this survey among 17 International League Against Epilepsy level II epilepsy surgery centers. The consensus process involved a rigorous, multi-step questionnaire that included 257 questions in the first round and 81 refined questions in the second round. These questions covered comprehensive clinical domains of diagnosis, imaging, medical and surgical treatment, neuropsychological and psychiatric evaluation, and postoperative care. The authors defined consensus as greater than or equal to 75 percent agreement using a 9-point Likert scale. Ultimately, consensus was achieved on 82 percent of the survey questions. These findings support a multidisciplinary, protocol-driven approach to optimize outcomes, providing practicing neurologists and neurosurgeons with a much-needed standardized framework for managing these complex cases.

Diagnostic Imaging and Seizure Semiology

When evaluating patients for suspected hypothalamic hamartomas, clinicians must pay close attention to specific seizure semiology. The expert consensus panel agreed that gelastic and dacrystic seizures are strongly associated with hypothalamic hamartomas and are important at diagnosis. Gelastic seizures (characterized by sudden outbursts of mirthless laughter) and dacrystic seizures (marked by involuntary crying) serve as critical clinical indicators for these rare lesions. To confirm the diagnosis, the experts established that a 3-Tesla epilepsy protocol MRI scan is essential. This high-resolution imaging provides the necessary anatomical detail to identify these deep-seated lesions, which might easily be missed on standard, lower-resolution scans.

While high-resolution MRI is mandatory, the consensus guidelines provide clear boundaries on what constitutes unnecessary testing. The panel concluded that evaluation with further imaging, specifically positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetoencephalography (MEG), is not useful. MEG, a non-invasive technique that maps brain activity by recording magnetic fields produced by electrical currents, does not add actionable clinical value for these specific lesions. Furthermore, the experts agreed that intracranial electroencephalography (EEG) is also not useful in the diagnostic workup. By explicitly advising against these advanced imaging modalities and invasive monitoring techniques, the consensus helps clinicians streamline the diagnostic process, reduce healthcare costs, and avoid subjecting patients to low-yield procedures.

Fast-Tracking Surgical Evaluation Over Medical Management

The management of hypothalamic hamartomas presents a stark contrast between medical and surgical pathways. The expert panel noted a striking lack of agreement regarding pharmacological treatment; specifically, no consensus was achieved on first-line, second-line, or third-line antiseizure medications (ASMs). Because these lesions are highly epileptogenic and often refractory to medical therapy, the guidelines strongly advocate for an accelerated surgical timeline. The consensus dictates that surgical evaluation should begin at the start of the first ASM. Furthermore, rather than subjecting patients to prolonged trials of ineffective drugs, surgery is recommended after the failure of two ASMs. This aggressive timeline underscores the necessity of viewing surgery not as a last resort, but as a primary therapeutic strategy to prevent ongoing epileptic encephalopathy.

When patients transition to surgical intervention, clinicians have multiple operative strategies at their disposal. The consensus panel agreed that surgery should be pursued either by disconnective, ablative, or resective techniques, depending on the specific anatomical and clinical characteristics of the lesion. For specific anatomical classifications, laser interstitial thermal therapy (LITT) is preferred for Delalande II and III hypothalamic hamartomas. LITT is a minimally invasive surgical technique that uses a laser probe to deliver targeted heat to destroy abnormal tissue. The Delalande classification system categorizes these lesions based on their anatomical relationship to the third ventricle and hypothalamus, with types II and III indicating varying degrees of intraventricular and hypothalamic involvement. Finally, the experts emphasized that procedural success relies heavily on specific clinical and institutional factors, noting that hypothalamic hamartoma location, size, and surgical experience are essential for good surgical outcomes.

Comprehensive Neuropsychological and Postoperative Care

The management of hypothalamic hamartomas extends well beyond surgical intervention, requiring rigorous perioperative and postoperative monitoring. The consensus guidelines establish that preoperative and postoperative cognitive, behavioral, psychosocial, and endocrinologic evaluations are emphasized to track patient trajectories accurately. Clinicians must assess a broad spectrum of neurocognitive and psychiatric factors. Specifically, the panel identified that important evaluation domains include IQ, language, attention, executive function, academic achievement, adaptive function, and behavior. Within the behavioral domain, physicians should specifically monitor for tantrums, rage, anxiety, and depression, as these symptoms frequently complicate the clinical picture and severely impact quality of life. To ensure standardized follow-up, the experts agreed that neuropsychological testing should be obtained at baseline and 6 to 12 months postsurgically. This timeline allows clinicians to quantify surgical impacts on cognitive and behavioral development while identifying patients who may require additional psychosocial support.

Structural monitoring is equally critical in the postoperative phase. The consensus panel recommends that a postoperative MRI should be obtained at 6 to 12 months and/or if there are ongoing seizures. This imaging schedule helps clinicians verify the extent of lesion ablation or disconnection and investigate any recurrence of epileptic activity. Despite the high level of agreement achieved across most domains of management, the Delphi process also highlighted critical gaps in current clinical knowledge. The researchers noted that areas lacking consensus, such as specific endocrine testing and timing of certain interventions, warrant further research and standardization. Because hypothalamic hamartomas frequently disrupt the hypothalamic-pituitary axis, the absence of a unified protocol for specific hormone assays leaves a notable void in endocrinologic care. Future studies must address these specific diagnostic and temporal uncertainties to refine the multidisciplinary, protocol-driven approach required for these complex patients.

References

1. Soeby L, Webster E, Miller I. Hope for hypothalamic hamartomas—Cofounders stories. Epilepsia. 2014. doi:10.1111/epi.12514

2. Wagner K, Demerath T, Metzger SM, et al. Developmental and epileptic encephalopathy in patients with epilepsy due to hypothalamic hamartomas. Epilepsia. 2025. doi:10.1111/epi.18404

3. Ou Y, Yuan J, Li C. Direct resection is a safe and effective strategy to control seizures in patients with hypothalamic hamartoma. Scientific Reports. 2024. doi:10.1038/s41598-024-63480-3

4. Reinacher PC, Jacobs J, Shah M, et al. Long‐term outcomes of stereotactic radiofrequency ablation in hypothalamic hamartomas: A single‐center experience. Epilepsia. 2025. doi:10.1111/epi.18660

5. Mazhit A, Akbay B, Трофимов АН, Karapina O, Duysenbi S, Tokay T. Epileptogenesis and Epilepsy Treatment: Advances in Mechanistic Understanding, Therapeutic Approaches, and Future Perspectives. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031175

6. Cohen NT, Li X, Berl MM, et al. International Consensus on the Evaluation and Management of Hypothalamic Hamartomas: Results From a Modified Delphi Survey.. Neurology. 2026. doi:10.1212/WNL.0000000000214760